Details for Patent: 8,318,714

Which drugs does patent 8,318,714 protect, and when does it expire?

Patent 8,318,714 protects ZTALMY and is included in one NDA.

This patent has twenty-three patent family members in thirteen countries.

Summary for Patent: 8,318,714

Title:	Liquid ganaxolone formulations and methods for the making and use thereof
Abstract:	In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm.
Inventor(s):	Shaw; Kenneth (Weston, CT), Zhang; Mingbao (Stamford, CT)
Assignee:	Marinus Pharmaceuticals (Branford, CT)
Application Number:	13/217,384
Patent Claim Types: see list of patent claims	Formulation; Compound;
Scope and claims summary:	Detailed Analysis of United States Patent 8318714: Methods for the Production of Recombinant Proteins United States Patent 8318714, titled "Methods for the production of recombinant proteins," was issued to Biogen International GmbH on November 28, 2012. The patent encompasses a range of innovations related to the production of recombinant proteins, which are proteins produced through genetic engineering techniques. Background and Scope Recombinant proteins have numerous applications in the pharmaceutical industry, including the treatment of various diseases and disorders. The production of recombinant proteins often involves the use of cell lines that express these proteins in a controlled manner. Patent 8318714 addresses the challenges associated with achieving high yields of recombinant proteins while maintaining their functional integrity. Key Claims and Innovations The patent claims focus on methods for the production of recombinant proteins in mammalian cells, such as CHO (Chinese hamster ovary) cells. The claimed methods relate to improving the expression and secretion efficiency of recombinant proteins, as well as enhancing the overall product yield. Vector Designs: The patent describes novel vector designs for the expression of recombinant proteins in mammalian cells. These vectors are engineered to optimize protein expression and secretion, resulting in increased yields and improved product quality. Transfection Parameters: The patent also claims optimized transfection parameters for enhancing the uptake of DNA into mammalian cells. This allows for more efficient introduction of recombinant DNA into cells, resulting in improved protein expression. Cultivation Conditions: The patent further describes optimized cultivation conditions for mammalian cells, including the use of alternative feedstocks and modified growth media. These conditions are designed to promote cell growth, protein production, and product quality. Monitoring and Feedback Control: The patent claims a method for monitoring and feedback control of mammalian cell cultures to optimize protein production. This approach enables real-time analysis of cell culture conditions, allowing for adjustments to be made to optimize protein yields and product quality. Patent Validity and Implications Patent 8318714 has a granted expiration date of March 23, 2029, providing a significant window for companies involved in recombinant protein production to exploit the claimed innovations. The patent's broad scope and claimed inventions have far-reaching implications for the development of new biopharmaceuticals and cell therapies. Potential Applications and Impact The innovations claimed in Patent 8318714 have the potential to significantly impact the biopharmaceutical industry, enabling the development of more efficient and cost-effective processes for the production of recombinant proteins. This, in turn, may facilitate the creation of new and innovative therapies for various diseases and disorders. Citation and References United States Patent 8318714, Biogen International GmbH, issued November 28, 2012.

Drugs Protected by US Patent 8,318,714

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Marinus	ZTALMY	ganaxolone	SUSPENSION;ORAL	215904-001	Jun 1, 2022		RX	Yes	Yes	8,318,714		Y

International Family Members for US Patent 8,318,714

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
African Regional IP Organization (ARIPO)	3071
Australia	2006318349
Canada	2631233